[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351061-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351061-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","platelet-to-lymphocyte-ratio-for-prognostication-in-immune-checkpoint-inhibitor-treated-cancer-patients-a-meta-analysis-of-13027-patients-highlighting-nivolumab-responsive-renal-cell-carcinoma","Platelet-to-lymphocyte ratio for prognostication in immune checkpoint inhibitor-treated cancer patients - a meta-analysis of 13027 patients highlighting nivolumab-responsive renal cell carcinoma","","Elevated platelet-to-lymphocyte ratio (PLR) is evaluated as a prognostic biomarker for overall survival (OS) and progression-free survival (PFS) in immune checkpoint inhibitor (ICI) treated cancer patients. A systematic review and meta-analysis pooled hazard ratios from 98 publications including 13027 patients, using random-effects models. Results show higher PLR predicts shorter OS and PFS, with subgroup patterns varying by geography, cancer type, PLR cutoff, ICI class, treatment line, and tumor stage, especially in nivolumab-responsive renal cell carcinoma.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/platelet-to-lymphocyte-ratio-for-prognostication-in-immune-checkpoint-inhibitor-treated-cancer-patients-a-meta-analysis-of-13027-patients-highlighting-nivolumab-responsive-renal-cell-carcinoma/351061/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/platelet-to-lymphocyte-ratio-for-prognostication-in-immune-checkpoint-inhibitor-treated-cancer-patients-a-meta-analysis-of-13027-patients-highlighting-nivolumab-responsive-renal-cell-carcinoma/351061.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main objective of this study?","Question",{"text":63,"@type":64},"To assess whether platelet-to-lymphocyte ratio (PLR) predicts overall survival (OS) and progression-free survival (PFS) in cancer patients treated with immune checkpoint inhibitors, and to explore how results vary by key clinical factors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the meta-analysis conducted?",{"text":68,"@type":64},"A systematic search identified studies examining PLR and prognosis in ICI-treated patients. Hazard ratios with 95% confidence intervals were pooled using random-effects models, followed by subgroup analyses and publication bias assessment.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main findings regarding elevated PLR?",{"text":72,"@type":64},"Elevated PLR was associated with significantly shorter OS and PFS. The prognostic relevance was particularly robust in nivolumab-treated renal cell carcinoma, while PFS patterns varied across cancer types and ICI classes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351061,1790145807,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","TYPE Systematic Review PUBLISHED 02 February 2026 DOI 10.3389/fimmu.2026.1732790  \nOPEN ACCESS  \nEDITED BY  \nZhen Li,  \nQilu Hospital of Shandong University, China  \nREVIEWED BY  \nHasan Cagri Yildirim, Ege University, Türkiye Mustafa Murat Midik,  \nEge University Medical School, Türkiye  \n*CORRESPONDENCE  \nYi Zhong  \n [zhongzixian2000@163.com](zhongzixian2000@163.com)  \nRECEIVED 26 October 2025  \nREVISED 11 January 2026  \nACCEPTED 14 January 2026  \nPUBLISHED 02 February 2026  \nCITATION  \nWang M, Dong W, Chen J, Wu P, Wang Y, Zhang X, Cao Y, Wang Z, Zhong Z and Zhong Y (2026) Platelet-to-lymphocyte ratio for prognostication in immune checkpoint inhibitor-treated cancer patients: a metaanalysis of 13027 patients highlighting nivolumab-responsive renal cell carcinoma. Front. Immunol. 17:1732790 .  \ndoi: 10.3389/fimmu.2026.1732790  \nCOPYRIGHT  \n© 2026 Wang, Dong, Chen, Wu, Wang, Zhang, Cao, Wang, Zhong and Zhong. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nPlatelet-to-lymphocyte ratio for prognostication in immune checkpoint inhibitor-treated cancer patients: a meta-analysis of 13027 patients highlighting nivolumab-responsive  \nrenal cell carcinoma  \nMingxing Wang 1,2, Wanhui Dong 3, Jian Chen 1, Pantong Wu 1,2, Yuru Wang 1,2, Xiaonan Zhang 1,2, Yaning Cao 1,2, Zhiying Wang 2, Zhixian Zhong 4 and Yi Zhong 1,2*  \n1Shanghai TCM-Integrated Hospital, Shanghai University of TCM, Shanghai, China, 2 Department of Oncology, Shanghai University of Traditional Chinese Medicine, Shanghai, China, 3 Lu’an Hospital of Traditional Chinese Medicine Afﬁliated to Anhui University of Chinese Medicine, Lu’an, Anhui, China, 4 Department of Oncology, Tongji University, Shanghai, China  \nObjective: To assess platelet-to-lymphocyte ratio (PLR) prognostic utility for overall (OS) and progression-free survival (PFS) in immune checkpoint inhibitortreated cancer patients, and examine impacts of geography, cancer type, cutoff, ICI class, treatment line and stage.  \nMethods: A systematic literature search identiﬁed studies investigating PLR and prognosis in ICI treated patients. Hazard ratios (HRs) with 95% conﬁdence intervals (CIs) were pooled using random-effects models. Subgroup analyses examined key covariates; publication bias was assessed.  \nResults: Analysis of 98 publications (86 OS, 72 PFS) demonstrated that elevated PLR was a robust predictor of shorter OS (HR 1.79, 95% CI: 1.60-2.00) and PFS (HR 1.60, 95% CI: 1 .44-1.78) . Subgroup analyses revealed: (1) Geographic region: Asian populations exhibited the most consistent correlation with OS and the highest PFS risk (69%) . (2) Cancer type: For OS, prognostic value was maintained across all cancers; the most pronounced impacts were observed in hepatocellular carcinoma (HR 2.10), esophageal carcinoma (HR 2.08), and head and neck squamous cell carcinoma (HR 2 . 61) . For PFS, a notable link to poor outcomes was observed in NSCLC and hepatocellular carcinoma, whereas renal cell carcinoma showed no such correlation. (3) PLR cutoff: both PLR ≥180(OS: HR1 .87; PFS: HR 1 . 68)and PLR \u003C180 (OS: HR 1.73; PFS: HR 1.53) subgroups consistently yielded unfavorable outcomes. (4) ICI category: for OS, camrelizumab showed the strongest prognostic relevance (HR 4.68), whereas for PFS, all ICIs yielded consistent results. (5) Treatment line: both ﬁrst-line (OS: HR 1 .98; PFS: HR 1 .93) and secondline or beyond (OS: HR 1.87; PFS: HR 1.79) demonstrated clear prognostic utility without inter-subgroup differences. (6) Tumor stage: Advanced stages (III–IV, IIIB– IV, IV) conﬁrmed the predictive value of PLR for both OS and PF","cbCaiu5W2PrY1laB","https://ap.wps.com/l/cbCaiu5W2PrY1laB","pdf",8651680,22,"English","# Objective\n# Methods\n# Results\n## Prognostic effect of PLR\n## Subgroup analyses\n# Conclusions\n# Keywords\n# Introduction","[{\"question\":\"What is the main objective of this study?\",\"answer\":\"To assess whether platelet-to-lymphocyte ratio (PLR) predicts overall survival (OS) and progression-free survival (PFS) in cancer patients treated with immune checkpoint inhibitors, and to explore how results vary by key clinical factors.\"},{\"question\":\"How was the meta-analysis conducted?\",\"answer\":\"A systematic search identified studies examining PLR and prognosis in ICI-treated patients. Hazard ratios with 95% confidence intervals were pooled using random-effects models, followed by subgroup analyses and publication bias assessment.\"},{\"question\":\"What were the main findings regarding elevated PLR?\",\"answer\":\"Elevated PLR was associated with significantly shorter OS and PFS. The prognostic relevance was particularly robust in nivolumab-treated renal cell carcinoma, while PFS patterns varied across cancer types and ICI classes.\"}]","Platelet-to-lymphocyte ratio for prognostication in immune checkpoint inhibitor-treated cancer patients - a meta-analysis of 13027 patients highlighting nivolumab-responsive renal cell carcinoma | PDF",1790092445,55,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8800847608f6ec7c3bb2d77c3fa278ca.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c05e52481572579e82bd0bfa9f8ffd11.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bba4d7832240de1861f1ffb9e6e9aaf4.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/568e730d75e9ff700590b7fcbf60affa.webp",980,1385]